Search Results - "Røge, Birgit T."

Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial by Madsen, Lone W, Christensen, Peer B, Hansen, Janne F, Røge, Birgit T, Holm, Dorte K, Dröse, Sandra, Øvrehus, Anne

“…Enhancing treatment uptake for hepatitis C to achieve the elimination goals set by the World Health Organization could be achieved by reducing the treatment…”
Get full text

Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations by Sølund, Christina, Krarup, Henrik, Ramirez, Santseharay, Thielsen, Peter, Røge, Birgit T, Lunding, Suzanne, Barfod, Toke S, Madsen, Lone G, Tarp, Britta, Christensen, Peer B, Gerstoft, Jan, Laursen, Alex L, Bukh, Jens, Weis, Nina

“…The first standard of care in treatment of chronic HCV genotype 1 infection involving directly acting antivirals was protease inhibitors telaprevir or…”
Get full text

Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non‐target sites, for DAA‐based treatment and retreatment outcome by Fahnøe, Ulrik, Pedersen, Martin S., Sølund, Christina, Ernst, Anja, Krarup, Henrik B., Røge, Birgit T., Christensen, Peer B., Laursen, Alex L., Gerstoft, Jan, Thielsen, Peter, Madsen, Lone G., Pedersen, Anders G., Schønning, Kristian, Weis, Nina, Bukh, Jens

“…Direct‐acting antivirals (DAAs) have proven highly effective against chronic hepatitis C virus (HCV) infection. However, some patients experience treatment…”
Get full text

Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation by Sølund, Christina, Hallager, Sofie, Pedersen, Martin S., Fahnøe, Ulrik, Ernst, Anja, Krarup, Henrik B., Røge, Birgit T., Christensen, Peer B., Laursen, Alex L., Gerstoft, Jan, Bélard, Erika, Madsen, Lone G., Schønning, Kristian, Pedersen, Anders G., Bukh, Jens, Weis, Nina

“…Objectives: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who…”
Get full text

Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study by Sølund, Christina, Andersen, Ellen S, Mössner, Belinda, Laursen, Alex L, Røge, Birgit T, Kjær, Mette S, Gerstoft, Jan, Christensen, Peer B, Pedersen, Martin S, Schønning, Kristian, Fahnøe, Ulrik, Bukh, Jens, Weis, Nina

“…OBJECTIVENew potent direct-acting antiviral (DAA) regimens against hepatitis C virus have been approved in recent years. However, information about the rate of…”
Get full text

K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine by RØGE, Birgit T, KATZENSTEIN, Terese L, OBEL, Niels, NIELSEN, Henrik, KIRK, Ole, PEDERSEN, Court, MATHIESEN, Lars, LUNDGREN, Jens, GERSTOFT, Jan

“…Antiretroviral treatment with three nucleoside reverse transcriptase inhibitors (NRTIs) is widely used, but the combination of abacavir, didanosine and…”
Get full text

Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated p-lactate levels by RØGE, Birgit T, CALBET, José A. L, MØLLER, Kirsten, ULLUM, Henrik, HENDEL, Helle W, GERSTOFT, Jan, PEDERSEN, Bente K

“…To investigate the skeletal muscle mitochondrial function in HIV-infected patients with lipodystrophy or elevated p-lactate levels. Eight HIV patients treated…”
Get full text

Comparison of P-Triglyceride Levels among Patients with Human Immunodeficiency Virus on Randomized Treatment with Ritonavir, Indinavir or Ritonavir/Saquinavir by RØGE, Birgit T, KATZENSTEIN, Terese L, GERSTOFT, Jan

“…This study compared the alterations in p-triglyceride (PT) in 111 protease inhibitor (PI)-naive patients on randomized treatment with either indinavir (800 mg…”
Get full text

Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: A nationwide population-based cohort study by Larsen, Mette Vang, Omland, Lars Haukali, Gerstoft, Jan, Røge, Birgit T., Larsen, Carsten Schade, Pedersen, Gitte, Obel, Niels, Kronborg, Gitte

“…Abstract The objective of this study was to determine the effect of highly active antiretroviral therapy (HAART) in human immunodeficiency virus (HIV)-infected…”
Get full text

Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations by MATHIESEN, Sofie, ROGE, Birgit T, WEIS, Nina, LUNDGREN, Jens D, OBEL, Niels, GERSTOFT, Jan

Get full text

Drug resistance mutations and outcome of second‐line treatment in patients with first‐line protease inhibitor failure on nelfinavir‐containing HAART by Røge, BT, Katzenstein, TL, Nielsen, HL, Gerstoft, J

“…Objectives To determine resistance mutations emerging in HIV‐1‐infected patients experiencing their first protease inhibitor (PI)‐failure on…”
Get full text

Natural History of Hyperlactataemia in Human Immunodeficiency Virus-1-infected Patients During Highly Active Antiretroviral Therapy by HUYNH, TUAN K., LÜTTICHAU, HANS R., ROGE, BIRGIT T., GERSTOFT, JAN

“…A study on the course of hyperlactataemia during highly active antiretroviral therapy (HAART) and the association between hyperlactataemia and antiretroviral…”
Get full text